Your browser doesn't support javascript.
loading
Trends in HbA1c and Body Mass Index Among Individuals with Type 2 Diabetes: Evidence from a US Database 2012-2019.
Boye, Kristina S; Lage, Maureen J; Shinde, Shraddha; Thieu, Vivian; Bae, Jay Patrick.
Afiliação
  • Boye KS; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
  • Lage MJ; HealthMetrics Outcomes Research, 27576 River Reach Drive, Bonita Springs, FL, 34134, USA. lagemj@hlthmetrics.com.
  • Shinde S; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
  • Thieu V; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
  • Bae JP; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.
Diabetes Ther ; 12(7): 2077-2087, 2021 Jul.
Article em En | MEDLINE | ID: mdl-34076849
ABSTRACT

INTRODUCTION:

Given the high rates of obesity and poor glycemic control among individuals with type 2 diabetes (T2D), this study examines current trends in HbA1c and body mass index (BMI) as well as the association between HbA1c and BMI among adults with T2D.

METHODS:

Data from the IBM® MarketScan® Explorys® Claims-EMR Data were used to construct eight annual cohorts for the years 2012-2019. Each annual cohort included adults identified with T2D who had at least one recorded HbA1c laboratory result and BMI value in the year of interest. Given these cohorts, trends in HbA1c and BMI were described over time using generalized estimating equation (GEE) tests.

RESULTS:

Results indicate that, over the study period from 2012-2019, average BMI increased significantly and there was a decrease in the percentage of adults with T2D who achieved glycemic control. In addition, for all years, higher BMI classification was associated with higher HbA1c values. When examining results for patients in different age groups, the findings were generally consistent with the overall population. In each age group, but most notably the age 18-44 group, the mean BMI increased over time and higher BMI was associated with higher HbA1c.

CONCLUSION:

Given the increase in BMI and decreasing percentage of individuals achieving glycemic control among adults with T2D found over the study period, therapies which decrease BMI as well as HbA1c can potentially have a significant impact on the management of T2D. The growing proportion of the younger age group with higher mean BMI may remain a key subgroup of interest.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article